Corvia Medical Secures $55 Million Financing for FDA Approval

Deal News | Jun 17, 2025 | PR Newswire Cision Corvia Medical, Inc.

Corvia Medical, Inc., based in Tewksbury, Massachusetts, has successfully closed a $55 million financing round to complete their RESPONDER-HF trial and seek FDA approval for their Corvia atrial shunt. This second, international, randomised, sham-controlled confirmatory trial is conducted across over 65 institutions on three continents. The atrial shunt strives to manage heart failure with preserved and mildly reduced ejection fraction by reducing elevated left atrial pressure, addressing a significant unmet medical need. The investment, led by existing investors such as Third Rock Ventures and General Catalyst Partners, signals strong ongoing support for Corvia's transformative heart failure treatment mission. With this funding, Corvia aims to secure FDA approval to introduce this innovative therapy globally.

Sectors

  • Medical Devices
  • Healthcare
  • Venture Capital

Geography

  • United States – Corvia Medical is headquartered in Tewksbury, Massachusetts, and its activities are centered around securing FDA approval, which is a US regulatory process.

Industry

  • Medical Devices – Corvia Medical develops innovative cardiovascular devices, specifically their atrial shunt for heart failure treatment.
  • Healthcare – The company's focus on creating solutions for heart failure positions it in the broader healthcare industry.
  • Venture Capital – The involvement of investor groups like Third Rock Ventures indicates this sector's relevance to the article.

Financials

  • $55 million – The total amount raised in the recent financing round to further Corvia's clinical trials and FDA approval process.

Participants

NameRoleTypeDescription
Corvia Medical, Inc.Target companyCompanyA Massachusetts-based company developing novel cardiovascular devices.
Third Rock VenturesInvestorCompanyA key investor in the financing round for Corvia.
General Catalyst PartnersInvestorCompanyAn investor supporting the financial round for Corvia Medical.
AccelMedInvestorCompanyPart of the investment syndicate backing Corvia's clinical trials and FDA approval efforts.
Lumira VenturesInvestorCompanyAn investor contributing to the $55 million funding for Corvia.
George FazioCEOPersonCEO of Corvia Medical, expressing gratitude for investor support.
Paul LaVioletteChairman of the BoardPersonChairman at Corvia Medical, highlighting the company’s potential in altering heart failure treatment.